Jefferies Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.7M	Sell	466,258 -1,888	-0.4%	-$103K	0.18%	113
2026 Q1	$26.4M	Buy	468,146 +1,128	+0.2%	+$65.8K	0.18%	89
2025 Q4	$27.8M	Buy	+467,018	New	+$25.4M	0.14%	140
2025 Q2	–	Sell	-6,169	Closed	-$436K	–	1324
2025 Q1	$436K	Buy	+6,169	New	+$415K	﹤0.01%	1086
2024 Q4	–	Sell	-4,350	Closed	-$306K	–	1604
2024 Q3	$306K	Buy	+4,350	New	+$364K	﹤0.01%	1111
2024 Q2	–	Sell	-10,600	Closed	-$926K	–	1435
2024 Q1	$926K	Buy	10,600 +379	+4%	+$33.9K	0.01%	850
2023 Q4	$986K	Buy	10,221 +7,231	+242%	+$640K	0.01%	958
2023 Q3	$265K	Sell	2,990 -2,023	-40%	-$180K	﹤0.01%	1261
2023 Q2	$435K	Sell	5,013 -22,904	-82%	-$2.16M	﹤0.01%	1224
2023 Q1	$2.71M	Sell	27,917 -17,855	-39%	-$1.85M	0.02%	555
2022 Q4	$4.74M	Buy	+45,772	New	+$4.3M	0.03%	417

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jefferies Financial Group's BMRN Position: Q2 2026 in Review

Jefferies Financial Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.4% in Q2 2026, selling an estimated $103K and leaving 466,258 shares worth $26.7M. The position accounts for 0.18% of the portfolio, ranked #113.

Jefferies Financial Group first reported a position in BMRN in Q4 2022 and has held it in 11 quarters since. The position peaked at $27.8M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Jefferies Financial Group held 466,258 shares of BioMarin Pharmaceuticals worth $26.7M as of Q2 2026.
Jefferies Financial Group sold 1,888 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $103K.
BioMarin Pharmaceuticals made up 0.18% of Jefferies Financial Group's portfolio in Q2 2026, its #113 holding.
Jefferies Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Jefferies Financial Group's BioMarin Pharmaceuticals position peaked at $27.8M in Q4 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.